

Date: 21/08/2026
Our Ref: 11753
Enquiries to loth.freedomofinformation@nhs.scot

Dear

FREEDOM OF INFORMATION – CANCER TREATMENT

I write in response to your request for information in relation to cancer treatment in NHS Lothian.

Question:

1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Abiraterone (Zytiga or generic abiraterone); Apalutamide (Erleada); Cabazitaxel; Darolutamide (Nubeqa); Docetaxel; Enzalutamide (Xtandi); Lutetium-177 PSMA-617 (Pluvicto); Olaparib (Lynparza); Relugolix (Orgovyx, Ryeqo); Talazoparib (Talzenna)

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Patients treated, NHS Lothian	
Name of medicine	Number of patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	87
1.2 Apalutamide (Erleada)	≤5
1.3 Cabazitaxel	9
1.4 Darolutamide (Nubeqa)	6
1.5 Docetaxel	79
1.6 Enzalutamide (Xtandi)	34
1.7 Lutetium-177 PSMA-617 (Pluvicto)	0
1.7 Olaparib (Lynparza)	22
1.8 Relugolix (Orgovyx, Ryeqo)	Data unavailable, requires linkage
1.9 Talazoparib (Talzenna)	0

Question:

2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Docetaxel for prostate cancer; Olaparib (Lynparza) for prostate cancer; Talazoparib (Talzenna) for prostate cancer; Relugolix (Orgovyx) for prostate cancer.

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Treatment for prostate cancer, NHS Lothian	
Name of medicine	Number of patients treated
2.1 Docetaxel for prostate cancer	17
2.2 Olaparib (Lynparza) for prostate cancer	≤5
2.3 Talazoparib (Talzenna) for prostate cancer	0
2.4 Relugolix (Orgovyx) for prostate cancer	Data unavailable, requires linkage

Question:

3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Abiraterone (Zytiga or generic abiraterone); Apalutamide (Erleada); Cabazitaxel (Jevtana or generic cabazitaxel); Darolutamide (Nubeqa); Enzalutamide (Xtandi).

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Patients treated in first cycle or first dose, NHS Lothian	
Name of medicine	Number of patients treated in dose 1 or cycle 1
3.1 Abiraterone (Zytiga or generic abiraterone)	22
3.2 Apalutamide (Erleada)	≤5
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	≤5

Patients treated in first cycle or first dose, NHS Lothian	
Name of medicine	Number of patients treated in dose 1 or cycle 1
3.4 Darolutamide (Nubeqa)	≤5
3.5 Enzalutamide (Xtandi)	20

Question:

4. How many patients were treated with the following combinations in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

Darolutamide (Nubeqa) + Docetaxel; Darolutamide (Nubeqa) monotherapy; Olaparib (Lynparza) + Abiraterone.

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Patients treated, NHS Lothian		
Name of medicine	Total number of patients treated	Number of patients treated in cycle 1 or dose 1
4.1 Darolutamide (Nubeqa) + Docetaxel	0	0
4.2 Darolutamide (Nubeqa) monotherapy	6	≤5
4.3 Olaparib (Lynparza) + Abiraterone	0	0
4.1 Darolutamide (Nubeqa) + Docetaxel	0	0
4.2 Darolutamide (Nubeqa) monotherapy	6	≤5

Question:

5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Abiraterone; Enzalutamide

Answer:

The information you have requested is detailed in the table below.

Patients treated for non metastatic hormone sensitive prostate cancer, NHS Lothian	
Name of medicine	Number of patients treated
5.1 Abiraterone	39
5.2 Enzalutamide	0

Question:

6. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between 1st April 2026 to the end of June 2026, or latest 3-month period for which data is available?

Darolutamide in combination with androgen deprivation therapy (ADT) for the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel (TA1109)

Answer:

This information is not collected centrally. This is because the pharmacy data for this treatment is not linked with diagnosis. Information may be held in individual patient records, but in order to provide the information you request it would be necessary to review each patient record over the period you have specified, requiring significant resources. Under section 12 of the Freedom of Information (Scotland) Act 2002, NHS Lothian is not required to respond to your request if the resources required to do so equate to more than £600 in cost.

Question:

7. How many patients received the following products for Non-Small Cell Lung Cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Atezolizumab (Tecentriq); Cemiplimab (Libtayo); Durvalumab (Imfinzi); Nivolumab (Opdivo)

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Patients treated for non small cell lung cancer, NHS Lothian	
Name of medicine	Number of patients treated
7.1 Atezolizumab (Tecentriq)	≤5
7.2 Cemiplimab (Libtayo)	0
7.3 Durvalumab (Imfinzi)	9
7.4 Nivolumab (Opdivo)	≤5

Patients treated for non small cell lung cancer, NHS Lothian	
Name of medicine	Number of patients treated
7.5 Pembrolizumab (Keytruda)	≤5

Question:

8. How many patients received the following products for Non-Small Cell Lung Cancer as *Neo-adjuvant or Adjuvant* treatment in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Atezolizumab; Durvalumab; Nivolumab; Pembrolizumab; Durvalumab.

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Patients treated for non small cell lung cancer as neoadjuvant or adjuvant treatment, NHS Lothian	
Name of medicine	Number of patients treated
8.1 Atezolizumab	≤5
8.2 Durvalumab	9
8.3 Nivolumab	≤5
8.4 Pembrolizumab	6
8.5 Durvalumab	9

Question:

9. How many patients received the following combination or monotherapy for Non-Small Cell Lung Cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?

Cemiplimab + Cisplatin or Carboplatin chemotherapy; Cemiplimab monotherapy

Answer:

The information you have requested is detailed in the table below.

Patients treated for non small cell lung cancer, NHS Lothian	
Name of medicine	Number of patients treated
9.1 Cemiplimab + Cisplatin or Carboplatin chemotherapy	0
9.2 Cemiplimab monotherapy	0

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at <https://www.foi.scot/appeal>. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI>

Yours sincerely

ALISON MACDONALD
Executive Director of Nursing Midwifery and AHPs
Cc: Chief Executive